Clinical Trial Detail

NCT ID NCT02352558
Title A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Boston Biomedical, Inc
Indications

hematologic cancer

Therapies

Imatinib

Napabucasin

Bortezomib

Ibrutinib

Dexamethasone

Age Groups: adult

No variant requirements are available.